Loading clinical trials...
Loading clinical trials...
A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Kyungpook National University Chilgok Hospital
Daegu, Daegu, South Korea
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Yongin Severance Hospital, Yonsei University Health System
Yongin, Gyeonggi-do, South Korea
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Seoul, Seoul, South Korea
Chung-Ang University Hospital
Seoul, Seoul, South Korea
Ewha Womans University Seoul Hospital
Seoul, Seoul, South Korea
Start Date
April 1, 2026
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
March 19, 2026
135
ESTIMATED participants
Shingrix
BIOLOGICAL
CVI-VZV-001
BIOLOGICAL
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
NCT07378059
NCT06932523
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06903078